The endocannabinoid system as a target for the treatment of cannabis dependence
about
Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalisState of the art treatments for cannabis dependenceProgress toward pharmacotherapies for cannabis-use disorder: an evidence-based reviewLipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and QuantificationCognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A ReceptorsDopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D2-induced formation of anandamideIndividual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.Animal models of cannabinoid reward.Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation.Pharmacological treatment of cannabis dependence.Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context.The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeysBehavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trialsThe endocannabinoid system: an overview.Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.Examining the effects of former cannabis use on cerebellum-dependent eyeblink conditioning in humans.Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.Marijuana dependence: not just smoke and mirrors.Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeysEffects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.[Pharmacological and psychosocial interventions for cannabis use disorders].Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cellsAbuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.Using dopamine research to generate rational cannabinoid drug policy.[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users.Baclofen in the management of cannabis dependence syndrome.Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB.Physical activity and cannabis cessation.Scientific Opinion on the safety of hemp (Cannabis genus) for use as animal feedCannabidiol for the treatment of cannabis withdrawal syndrome: a case report.Endocannabinoids and Schizophrenia.Inactivation of Anandamide Signaling: A Continuing Debate.
P2860
Q21142667-A39E7099-D1FC-4A38-A80C-6943973FDD11Q24607810-3B3E3FA9-A25A-43B3-9CF9-B616B274449AQ26746192-ADAA7907-7A54-4491-AD2A-2100C4AAAA00Q26769959-2F02C285-59C9-4E0F-8E89-87CEAE09F37DQ27347603-FD881916-5A83-44C8-895C-C758F5F179A4Q28972550-45A5A51D-2D34-488E-A68D-90045E3098F4Q33645739-22B15359-13C2-4B40-83E1-CE59953664DDQ34098204-B866D5C2-672C-4F72-999D-5254B1B968F8Q34718086-0FA70CD5-AA65-47AD-BB93-8C9EDDE9A221Q35210350-0ED93C39-8336-4CDA-A875-80F4F15A6AA0Q35222716-2BBE9F64-1446-4A7B-A325-743E8830360DQ35287465-81999B0F-FCC1-4E6F-B4F2-82BA8C1DF971Q35600998-293A93A2-F637-438A-9FCB-C456CFA0BCA3Q35828434-BAE018D9-C98D-419E-9481-DD20F8EC48E5Q36408464-6D12078B-01ED-42D9-88C8-A6FC2DEC8CEEQ36455159-9021E8CF-CF73-4398-A61B-01E89B204EE2Q36496045-CFFF1FF9-5227-457A-ADBD-97DC3CB42C1AQ36712200-0AB4E263-567F-457B-9171-418A70201884Q36839896-F4037A00-515B-4F7B-99B9-415E2263AC20Q36840135-436C54E0-AA9A-4B7E-89F8-558AFC495615Q36948826-912B0FFB-0516-4FC8-AE6E-A5012AE3A6D7Q37214542-A28138B7-8EC3-44CC-BB8E-C0E07884E079Q37219066-449D1CEF-515D-4F7F-8948-86642D1E90BFQ37871980-C7E58B5E-31BF-43E0-960C-5FBDD07B0ED4Q38044684-1398C943-ACEB-4E89-9A90-7ADBF2C728A9Q39283967-7B559353-5532-4A51-B576-799972862BF2Q41879795-0E6BA009-A1E9-4CAE-AFA7-52CA09048ADFQ42652023-52EC8274-643C-4F6A-AC08-104AE1B2B375Q44995410-AC08E53B-7CED-411C-A7A7-53D19BF3D1EAQ47149506-914E130F-4597-4E52-8676-39F3FCB1DB50Q48216300-33723936-6EE0-4DE7-B57A-0EF5A4F509EDQ55452539-EA143C7A-F531-4C8C-A0DD-D9187B179855Q55506553-7735BD11-BD5D-4178-9F41-E2D19F4EB684
P2860
The endocannabinoid system as a target for the treatment of cannabis dependence
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The endocannabinoid system as a target for the treatment of cannabis dependence
@ast
The endocannabinoid system as a target for the treatment of cannabis dependence
@en
The endocannabinoid system as a target for the treatment of cannabis dependence
@nl
type
label
The endocannabinoid system as a target for the treatment of cannabis dependence
@ast
The endocannabinoid system as a target for the treatment of cannabis dependence
@en
The endocannabinoid system as a target for the treatment of cannabis dependence
@nl
prefLabel
The endocannabinoid system as a target for the treatment of cannabis dependence
@ast
The endocannabinoid system as a target for the treatment of cannabis dependence
@en
The endocannabinoid system as a target for the treatment of cannabis dependence
@nl
P2860
P3181
P1433
P1476
The endocannabinoid system as a target for the treatment of cannabis dependence
@en
P2093
Jason R Clapper
Regina A Mangieri
P2860
P304
P3181
P356
10.1016/J.NEUROPHARM.2008.07.018
P407
P478
56 Suppl 1
P577
2009-01-01T00:00:00Z